Global Next Generation Sequencing Market Report 2021: Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, Nanopore Sequencing, & Others

News provided by

May 17, 2021, 08:15 ET

DUBLIN, May 17, 2021 /PRNewswire/ -- The "Next Generation Sequencing Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

This report focuses on next generation sequencing market which is experiencing strong growth. The report gives a guide to the next generation sequencing market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Major players in the next generation sequencing market are Illumina Inc., Thermo Fisher Scientific Inc., BGI Group, Agilent Technologies Inc., Qiagen N.V., Hoffmann-La Roche AG, Eurofins Scientific, Oxford Nanopore Technologies, Pacific Biosciences, and 10x Genomics.

The global next generation sequencing market is expected to grow from $7.05 billion in 2020 to $9.04 billion in 2021 at a compound annual growth rate (CAGR) of 28.2%.

The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.

The market is expected to reach $23.15 billion in 2025 at a CAGR of 27%.

The next generation sequencing market consists of sales of devices and equipment used in next generation sequencing and related services by entities (organizations, sole traders and partnerships) that manufacture next generation sequencing equipment. Next-generation sequencing (NGS) is the catch-all concept used to describe a variety of different advanced sequencing technologies. Such technologies allow DNA and RNA to be sequenced much faster and cheaper than traditionally used Sanger sequencing, revolutionizing the study of genomics and molecular biology.

The high cost associated with next generation sequencing technologies is a key factor hampering the growth of the next generation sequencing market. The next generation sequencing market is facing challenges as many people find it difficult to afford the test due to the high cost. Consumables used for sequencing are the costliest portion of testing (68-72% of total cost) as machinery prices are higher in instances of rare disease.

According to a review published in 2018 on economic evaluations of exome and genome sequencing, the cost of the next generation genome sequencing ranges from $1906 to $24,810 for a single test. Therefore, the high cost of next generation sequencing is anticipated to restrict market growth over the forecast period.

The growing number of cases with chronic conditions such as cancer, AIDS, and thalassemia contributed to the growth of the next generation sequencing market. Chronic illnesses and disorders are on the rise around the world, and aging population and shifts in social behavior lead to a gradual increase in these widespread and expensive long-term medical issues.

Next-generation sequencing (NGS) is a versatile development tool utilized by researchers and clinicians across various cancer studies to recognize biomarkers that give guidance on treatments. The prevalence of chronic diseases is also expected to increase significantly, according to the World Health Organization. Hence, the increase in the number of chronic disease cases will increase the requirement for NGS sequencing and boosts revenues for the next generation sequencing market.

The technological advances are shaping the next generation sequencing market. Major companies operating in the sequencing industry are focusing on developing technologically advanced solutions for next generation sequencing.

For instance, in January 2018, Illumina, Inc. announced the launch of the next-generation sequencing (NGS) system - iSeq 100 Sequencing System. It delivers exceptional data accuracy with low capital cost expanding the reach to the maximum number of labs.

Key Topics Covered:

1. Executive Summary

2. Next Generation Sequencing Market Characteristics

3. Next Generation Sequencing Market Trends And Strategies

4. Impact Of COVID-19 On Next Generation Sequencing

5. Next Generation Sequencing Market Size And Growth
5.1. Global Next Generation Sequencing Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Next Generation Sequencing Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Next Generation Sequencing Market Segmentation
6.1. Global Next Generation Sequencing Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

NextSeq Systems
MiniSeq Systems
NovaSeq Systems
iSeq 100 Systems
Ion PGM Systems
Ion Proton Systems
Ion GeneStudio S5 Systems
PacBio RS II Systems
Sequel Systems
Others

6.2. Global Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Sequencing by Synthesis
Ion Semiconductor Sequencing
Single-molecule Real-time Sequencing
Nanopore Sequencing
Other Sequencing Technologies

6.3. Global Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Diagnostics
Drug Discovery
Other Applications

7. Next Generation Sequencing Market Regional And Country Analysis
7.1. Global Next Generation Sequencing Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Next Generation Sequencing Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

Illumina Inc.
Thermo Fisher Scientific Inc
BGI Group
Agilent Technologies Inc.
Qiagen N.V.
Hoffmann-La Roche AG
Eurofins Scientific
Oxford Nanopore Technologies
Pacific Biosciences
10x Genomics
Genomatix GmbH
PierianDx
Bio-Rad Laboratories Inc.
Roche Sequencing
NanoString
Genapsys
Long Read Solutions
LGC Limited
454 Life Sciences Corporation (Roche Holding AG)
Genewiz
Takara Bio
Nugen Technologies

For more information about this report visit https://www.researchandmarkets.com/r/p6iqii

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets